Blog

  • Dupixent Is Linked to a Higher Risk of Psoriasis in Patients With Atopic Dermatitis

    Dupixent Is Linked to a Higher Risk of Psoriasis in Patients With Atopic Dermatitis

    Patients with atopic dermatitis (AD) who were treated with Dupixent (dupilumab) had a 58% higher three-year risk of developing psoriasis compared to those receiving other non-topical therapies, according to a recent study published in JAMA Dermatology.

    Dupixent is a widely used biologic treatment for moderate to severe AD, a chronic skin condition caused by inflammation that shows up as red or discolored patches that are very itchy.

    While Dupixent has been proven effective and generally safe, a number of reports suggest that it may increase the risk of developing psoriasis—a different inflammatory skin disease typically involving scaly plaques that often feels more like stinging or burning.

    AD affects nearly 32 million people in the U.S., while psoriasis affects approximately 7.55 million U.S. adults aged 20 years and older.

    AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and psoriasis driven by Th17 inflammation, according to study authors.

    However, newer research has shown that these diseases can overlap in patients and may even share common pathways.

    Blocking IL-4 and IL-13—the immune signals targeted by Dupixent—may unintentionally shift the immune balance toward Th17 activity, which is associated with psoriasis.

    Dupixent is a widely used biologic treatment for moderate to severe AD, a chronic skin condition caused by inflammation that shows up as red or discolored patches that are very itchy.

    Some people receiving Dupixent for conditions such as asthma and alopecia areata have also developed psoriasis-like rashes, suggesting that the reaction may not be limited to those with AD.

    In addition, joint pain resembling psoriatic arthritis has been reported.

    While case reports have hinted at this connection for years, large-scale studies have been limited.

    Researchers of the study conducted this retrospective cohort study to determine whether patients with AD treated with Dupixent had a higher risk of developing psoriasis compared to those receiving other treatments.

    Deidentified health records from the TriNetX Global Network—which includes data from over 150 million patients across 17 countries—were used to identify eligible adults.

    Participants were included if they had at least two AD diagnoses 30 days apart and initiated treatment with either Dupixent or another systemic therapy.

    Patients with a history of psoriasis or prior use of similar biologics were excluded.

    The study tracked new psoriasis diagnoses for up to three years, beginning one month after treatment started.

    Researchers matched 9,860 Dupixent users to 9,860 control patients based on demographic and clinical factors to reduce bias.

    They used several statistical methods to compare the groups, including ways to track how many people developed psoriasis over time and how significant the risk was.

    Researchers also tested the results in different patient groups to make sure results were reliable.

    In addition, a separate group of asthma patients without AD was studied to confirm the findings.

    Results showed a 58% higher risk of psoriasis in the dupilumab group, though the absolute risk remained low.

    Strengths & Limitations

    This large study had several strengths, including the use of robust electronic health record data and a matched cohort design that reduced selection bias and allowed for a more accurate comparison between patients.

    Researchers adjusted for factors including age, sex, race, comorbidities and lab results.

    Multiple sensitivity and subgroup analyses, along with a validation study in patients with asthma, strengthened the reliability of the findings.

    However, the study also had limitations.

    Because the study was observational, it could not prove that Dupixent causes psoriasis.

    The EHR data also lacked details on disease severity, treatment response and medication dosage or duration.

    Some cases may have been misclassified due to limited diagnostic information, although efforts were made to reduce this risk.

    The authors suggest that Dupixent could act as a trigger, rather than the sole cause, of psoriasis in those with certain immune profiles.

    They recommend further research to better understand whether Dupixent also increases the risk of psoriatic arthritis and to explore differences among patient subgroups that may influence who is more vulnerable to these skin reactions.

    Continue Reading

  • expert reaction to study looking at underlying mechanisms of the known, rare side effect, vaccine-induced immune thrombosis and thrombocytopenia (VITT), associated with adenoviral Covid vaccines

    A study published in the NIHR’s Efficacy and Mechanism Evaluation journal looks at the mechanisms of a known rare side effect, vaccine-induced immune thrombosis (VITT) and thrombocytopenia, associated with adenoviral Covid vaccines.

     

    Prof Adam Finn, Professor of Paediatrics, University of Bristol, said:

    “This is a summary of the findings to date of several distinct pieces of research intended to increase our understanding of VITT.  The work was extensive, took a number of different approaches, and provided some additional evidence around the potential pathogenetic mechanisms.  However, a complete understanding of the genetic and environmental factors which drive these rare reactions remains elusive, partly because of the relatively small number of individuals affected who could be studied.”

     

     

    ‘Understanding mechanisms of thrombosis and thrombocytopenia with adenoviral SARS-CoV-2 vaccines: a comprehensive synopsis’ by Phillip LR Nicolson et al. was published in the NIHR’s Efficacy and Mechanism Evaluation journal.

    DOI: 10.3310/FFSS9010

     

     

    Declared interests

    Prof Adam Finn: “Adam Finn is a member of JCVI subcommittees relating to varicella-zoster, pneumococcal and respiratory syncytial virus vaccines and of the WHO working group on COVID19 vaccines.  He leads epidemiological research for the University of Bristol funded by Pfizer.  He undertakes paid consultancy for multiple vaccine development and manufacturing companies.  He was an investigator in trials of the Oxford-AstraZeneca COVID19 vaccine during the pandemic.”

    Continue Reading

  • Updated EHA-EMN Guidelines Include Melphalan Flufenamide for R/R Myeloma

    Updated EHA-EMN Guidelines Include Melphalan Flufenamide for R/R Myeloma

    R/R Multiple Myeloma | Image credit:

    © LASZLO – stock.adobe.com

    Updated guidelines from the European Hematology Association (EHA) and the European Myeloma Network (EMN) now include melphalan flufenamide (Pepaxti) for the treatment of patients with relapsed/refractory multiple myeloma.1

    Specifically, the guidelines recommend melphalan flufenamide for patients who have received multiple prior lines of therapy and whose disease is triple-class refractory. This addition to the guidelines is supported by level 1 evidence, and melphalan flufenamide carries a Grade B recommendation, according to an announcement from Oncopeptides. The guidelines also include melphalan flufenamide as an option for patients with even more advanced disease, such as those who have also been treated with CAR T-cell therapy or an antibody-drug conjugate.

    “The fact that [melphalan flufenamide] has received a recommendation by this expert group once again confirms the drug’s value in later lines of treatment and will support awareness of [melphalan flufenamide] as a treatment option,” Sofia Heigis, chief executive officer of Oncopeptides, stated in a news release. “We are happy to see [melphalan flufenamide] having the highest combination of recommendation and clinical evidence of all non–CAR T[-cell] therapies, supporting the use of [melphalan flufenamide] as the first choice in subsequent treatment of multiple myeloma.”

    In February 2021, the FDA granted accelerated approval to melphalan flufenamide in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior lines of therapy and whose disease is refractory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 CD38-directed monoclonal antibody.2 In August 2022, the European Commission approved melphalan flufenamide in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 3 prior lines of therapies, whose disease is refractory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-CD38 monoclonal antibody, and who have disease progression on or after the last therapy.3

    However, in February 2024, the FDA withdrew the indication for the combination, citing that a confirmatory study to further support the accelerated approval did not confirm the clinical benefit of the agent, and available evidence had not demonstrated that melphalan flufenamide is safe or effective under its conditions of use.4

    The initial accelerated approval was supported by findings from the multicenter, single-arm phase 2 HORIZON trial (NCT02963493), which showed that patients previously treated with 4 or more prior lines of therapy who had triple-class refractory disease (n = 97) achieved an overall response rate of 23.7% (95% CI, 15.7%-33.4%) and a median duration of response of 4.2 months (95% CI, 3.2-7.6).2

    Regarding safety (n = 157), the most common adverse effects reported in more than 20% of patients included fatigue, nausea, diarrhea, pyrexia, and respiratory tract infection. Common laboratory abnormalities that occurred in more than 50% of patients comprised decreased leukocyte counts, decreased platelet counts, reduced lymphocyte counts, decreased neutrophil counts, lowered hemoglobin levels, and increased creatinine levels.

    The confirmatory phase 3 OCEAN trial (NCT03151811) included patients with relapsed or refractory multiple myeloma who were refractory to lenalidomide (Revlimid) and their last line of therapy.5 Patients needed to have received 2 to 4 prior lines of therapy.

    Findings showed that at a median follow-up of 15.5 months (interquartile range [IQR], 9.4-22.8) for the experimental arm and 16.3 months (IQR, 10.1-23.2) in the control arm, melphalan flufenamide plus dexamethasone (n = 246) yielded a median progression-free survival of 6.8 months (95% CI, 5.0-8.5) compared with 4.9 months (95% CI, 4.2-5.7) for pomalidomide (Pomalyst) plus dexamethasone (n = 249; HR, 0.79; 95% CI, 0.64-0.98; P = .032).5

    The median overall survival was 19.8 months (95% CI, 15.1-25.6) for the melphalan flufenamide group vs 25.0 months (95% CI, 18.1-31.9) for the pomalidomide group (HR 1.10; 95% CI, 0.85-1.44; P = .47).

    References

    1. Oncopeptides’ drug Pepaxti included in European Guidelines for the treatment of multiple myeloma. News release. Oncopeptides. July 8, 2025. Accessed July 8, https://oncopeptides.com/en/media/press-releases/oncopeptides-drug-pepaxti-included-in-european-guidelines-for-the-treatment-of-multiple-myeloma/
    2. FDA grants accelerated approval to melphalan flufenamide for relapsed or refractory multiple myeloma. FDA. February 26, 2021. Accessed July 8, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-fda-grants-accelerated-approval-melphalan-flufenamide-relapsed-or-refractory-multiple
    3. European Commission approves Oncopeptides’ Pepaxti for the treatment of patients with relapsed refractory multiple myeloma. News release. Oncopeptides AB. August 18, 2022. Accessed July 8, 2025. https://www.prnewswire.com/news-releases/european-commission-approves-oncopeptides-pepaxti-for-the-treatment-of-patients-with-relapsed-refractory-multiple-myeloma-301608459.html
    4. FDA issues final decision to withdraw approval of Pepaxto (melphalan flufenamide). FDA. February 23, 2024. Accessed July 8, 2025. https://www.fda.gov/drugs/drug-safety-and-availability/fda-issues-final-decision-withdraw-approval-pepaxto-melphalan-flufenamide
    5. Schjesvold FH, Dimopoulos MA, Delimpasi S, et al. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Lancet Haematol. 2022;9(2):e98-e110. doi:10.1016/S2352-3026(21)00381-1

    Continue Reading

  • New Discovery Reveals How Electric Rays Deter Predatory Sharks By Shocking Them

    New Discovery Reveals How Electric Rays Deter Predatory Sharks By Shocking Them

    Scientists were puzzled as to why it was that the electric rays of Guadalupe Island, Mexico, were so confident in the face of pretty sizable sharks. Turns out, they can zap these would-be predators – and the message is very effective, as demonstrated in footage of the behavior.

    “I believe this highlights the incredible defensive traits some animals have,” said study author and Assistant Professor at Florida International University, Yannis Papastamatiou, to IFLScience. “A lot of defensive traits appear ineffective against big predators (e.g. large sharks eat stingrays often; the barb doesn’t seem to deter them). At least from our limited observations, electric rays may be very effective at deterring large predators.”

    It paints the picture of a highly effective defensive mechanism!

    Yannis Papastamatiou

    The team hadn’t set out to uncover the zapping tendencies of rays around the island. They were deploying camera tags on white sharks, intending to study their social hunting, but once they spotted what was going on, they (too) were stunned.

    “I was so surprised I waited until there was more evidence, which we got when we saw the tiger shark footage,” said Papastamatiou. “When taken in combination with other observations, like their boldness in the water, it paints the picture of a highly effective defensive mechanism!”

    Rays are more typically associated with defensive strategies like camouflage (some look like sandy pancakes), venom and barbs (hello stingrays), and spines that make them a less swallowable meal (though some get used as scratching posts), but as Papastamatiou highlighted, these rarely stop big sharks from eating them. Now, it appears that one group of rays has found a way to thrive in dangerous waters by sending out electric discharges to any sharks that get too close.

    The rays here occupy a high position in the water column, which is about as dangerous as it gets when it comes to the ocean. There are an estimated 69 species of electric rays belonging to four separate families, all equipped with electric organ discharge (EOD) that in some of the larger species can go up to 50 volts. We didn’t know exactly how they were deploying that talent, however, until now.

    Case study one, included in a new paper about the behavior, details the deployment of Customized Animal Tracking Solutions (CATS) biologgers attached to white sharks that revealed some intriguing data. One shark taking a casual cruise at 50 meters (164 feet) depth approached an electric ray in the midwater before suddenly ascending to 30 meters (100 feet). Two minutes later, it returned to the previous depth, but gave the ray a wide berth. The ray itself seemed totally unfazed by the entire episode, carrying on with its business like only a badass can.

    Another case study included a shark that was captured on camera getting done in by the Gulf torpedo ray’s not-so-secret weapon. It was a tiger shark approaching a ray in Fuvahmulah, Maldives, only to whip out its nictitating membrane as it got near. Also known as the “third eyelid”, these membranes are deployed as a defensive strategy to shield the eye from harm.

    The third case study looked at the electrical discharges produced by Pacific electric rays during field experiments off Palos Verdes, California. The rays were provoked into discharging defensive and predatory shocks to see how they differed, and the results showed that while they didn’t vary in maximum voltage, predatory shocks were longer and more abundant.

    The study provides fresh insights into the evolution of defensive traits in marine animals, and it’s hoped that further study using biologging set ups could lift the lid on exactly what gives these rays so much damn confidence. “We still have so much to learn!” Papastamatiou said.

    The study is published in Ethology.

    Continue Reading

  • The Last of Us Part II’s new mode puts the story in chronological order

    The Last of Us Part II’s new mode puts the story in chronological order

    With season 2 of HBO’s The Last of Us in the books, and with no The Last of Us Part III coming in the immediate future, Naughty Dog has come up with an interesting way to funnel all the attention from the show into the game. The studio has released a new, free patch for The Last of Us Part II Remastered that lets you play the game in chronological order. The mode takes Abby and Ellie’s stories and interleaves them in chronological order rather than the nonlinear story of the original version of the game, which used timeskips and flashbacks.

    In addition to Chronological Mode, the patch also includes new achievements and skins to use in Part II Remastered’s roguelike game mode No Return. Now you can dress up Joel and his brother Tommy like Naughty Dog’s other pair of visually indistinct, emotionally constipated brothers; Nathan and Sam Drake. Naughty Dog does still recommend that first timers play TLOU Part II normally before tackling Chronological Mode but that, “the team’s hard work has paid off with a fascinating new way to enjoy this chapter.” Chronological Mode will give players a new reason to pick up the game while awaiting the next season of the show which will dive into events from Abby’s perspective. Season 3 though, will proceed without Neil Druckmann as co-lead. Druckmann, co-director of both The Last of Us games and creative director at Naughty Dog, recently announced that he’s taking a break from the show to focus efforts on the studio’s games including the recently announced, Intergalactic: The Heretic Prophet.

    Continue Reading

  • “Third Wheel” Star Brings Companions Closer Together

    “Third Wheel” Star Brings Companions Closer Together

    When white dwarfs—the hot remnants of stars like our Sun—are orbited closely by another star, they sometimes steal mass away from their companion. The stolen matter builds up on the surface of the white dwarf, triggering eruptions called novae.

    Theorists have long predicted how these volatile partnerships, called cataclysmic variables (CVs), form, but now a new Caltech-led study reveals a surprising twist: In some cases, a third star, circling farther away from the primary pair, may in fact be the reason the star couple got together in the first place.

    “Our results are revealing another formation channel for CVs,” says Kareem El-Badry, assistant professor of astronomy at Caltech and a co-author of a new paper appearing in the Publications of the Astronomical Society of the Pacific. “Sometimes, a lurking third star is key,” he says. The lead author of the study is Caltech graduate student Cheyanne Shariat.

    Before now, scientists believed that CVs formed from a process called common envelope evolution, in which the partner stars are brought closer together via an envelope of gas that cocoons them. An aging star destined to become a white dwarf expands into a red giant that encompasses both stars, creating a shared envelope. The envelope corrals the two stars, causing them to spiral inward. Eventually, the envelope is ejected, leaving a tight pair that have become close enough for the white dwarf to steal its companion’s mass.

    Although a third star was not mentioned in these descriptions, the team wondered if one could be involved. After all, they reasoned, triple-star dynamics do play a role in other types of star systems.

    To further investigate the matter, the researchers turned to data from the European Space Agency’s Gaia mission, now retired. Sorting through these observations, they identified 50 CVs in hierarchical triple-star systems, or triples, as the researchers call them. A hierarchical triple is one in which two stars are located fairly close together, while the third is much farther out and orbits the primary pair. The results suggested that at least 10 percent of all known CVs are part of triple systems.

    That 10 percent number was higher than what would be expected if triples had no role in CV formation, so the researchers decided to learn more by running computer simulations. They performed so-called three-body simulations on 2,000 hypothetical triples; these simulations sped up the gravitational interactions of the trio of stars, evolving them over time.

    In the triple-star simulations, CVs formed without the traditional mechanism of common envelope evolution 20 percent of the time. In these cases, the researchers say, the third star torqued the main binary.

    “The gravity of the third star causes the binary stars to have a super eccentric orbit, and this forces the companion star closer to the white dwarf. Tidal forces dissipate energy and shrink and circularize the orbit,” Shariat says. “The star doesn’t have to spiral in through the common envelope.”

    In 60 percent of the simulations, the triple star helped initiate the process of common envelope evolution, bringing the two primary stars close enough to one another to be encased in the same envelope. In the remaining 20 percent of the simulations, the CVs formed via the traditional common envelope evolution route that requires just two stars.

    When the researchers accounted for a realistic population of stars in our galaxy, including CVs known to have formed from just two stars, their theoretical models predicted around 40 percent of all CVs form in triple systems. This is higher than the 10 percent they observed using Gaia because, in many cases, the third stars can be either hard to see or have become unbound from the CV.

    Finally, the simulation results enabled predictions about the types of triple-star systems that would be more likely to form CVs. Specifically, the triple systems would be expected to start out in wider configurations, such that the tight-knit pair and the third star are separated by more than 100 astronomical units (an astronomical unit, or au, is the distance between the Sun and Earth).

    Looking back at the Gaia data, the researchers found agreement: The triples with CVs did exhibit wider separations on average than typical systems.

    “For the past 50 years, people were using the spiral-in common-envelope evolution model to explain CV formation,” El-Badry says. “Nobody had noticed before that this was largely happening in triples!”

    The study titled “Cataclysmic Variables in Triples: Formation Models and New Discoveries” was funded by the Joshua and Beth Friedman Foundation Fund, NASA, the National Science Foundation, and Howard and Astrid Preston. The project was done in collaboration with Smadar Naoz, a researcher at UCLA who specializes in theoretical studies of triples. Other authors include Antonio Rodriguez, a graduate student at Caltech, and Jan van Roestel of the University of Amsterdam.


    Continue Reading

  • A green and gold day for 2026 Pirelli tyre development

    A green and gold day for 2026 Pirelli tyre development

    After a spectacular British Grand Prix last weekend, Pirelli was back on track at Silverstone for two days of testing, aimed at development of the 2026 tyres.

    The task of collaborating on this complex and important phase of preparation for next season fell to Aston Martin, who were the first team to test the prototype tyres on track last September in Barcelona, this time joined by Sauber, who were trying this type of tyre for the very first time.

    Two Brazilians were driving today: Felipe Drugovich was behind the wheel of the Aston Martin AMR25, while Gabriel Bortoleto was driving the Sauber C45. Both cars were specially adapted to suit the 2026 tyres, which are 25 millimetres narrower at the front and 30 at the rear.

    Today’s work focused mainly on a comparison of the latest constructions prior to their being homologated, which is scheduled for this coming 1 September. Drugovich completed 112 laps, the quickest in 1’30”119 and Bortoleto did 110, the best being a 1’ 1’31’’341.

    Testing continues tomorrow with Sauber’s young Brazilian still driving, while Canada’s Lance Stroll takes over at Aston Martin. 

    ';

    Continue Reading

  • Chinese air force chief lauds PAF’s performance in conflict with India

    Chinese air force chief lauds PAF’s performance in conflict with India

    Listen to article


    ISLAMABAD:

    The Chief of Staff of China’s People’s Liberation Army Air Force (PLAAF), Lt General Wang Gang, praised the Pakistan Air Force (PAF) leadership for its professional acumen and strategic foresight while paying tribute to the exemplary performance of the PAF during the recent conflict with India.

    A high-level defence delegation, led by Lt General Gang, visited Chief of the Air Staff Air Chief Marshal Zaheer Ahmed Baber Sidhu at Air Headquarters in Islamabad on Tuesday, the military’s media wing reported.

    According to the Inter-Services Public Relations (ISPR), matters of mutual interest, regional security dynamics, and avenues for enhanced bilateral cooperation, particularly in airpower and operational synergy, were discussed during the meeting.

    Also Read: Chinese envoy praises PAF for ‘commendable utilisation of Chinese-origin equipment’

    Lt General Gang praised PAF pilots for delivering a decisive and measured response under the resolute leadership of Air Chief Marshal Sidhu, describing it as a textbook example of precision, discipline, and courage in the face of unprovoked aggression, the ISPR said.

    “He expressed deep appreciation for the high state of operational readiness and the cutting-edge capabilities of the Pakistan Air Force,” it added.

    The Chinese air chief was particularly impressed by the PAF’s seamless integration of Multi-Domain Operations, calling it a hallmark of modern air warfare. He conveyed the PLAAF’s keen interest in learning from the PAF’s battle-proven experience in Multi-Domain Operations, the statement read.

    On the occasion, Air Chief Marshal Sidhu warmly welcomed the distinguished guests and reiterated that Pakistan and China enjoy historic, time-tested ties rooted in mutual trust, strategic convergence, and shared aspirations for regional peace and stability, it added.

    Read More: South African Air Force chief visits Pakistan

    According to the ISPR, Lt General Gang was given a comprehensive briefing on the PAF’s modern force structure, strategic initiatives, and the evolution of its operational doctrine.

    Air Chief Marshal Sidhu also reaffirmed the strong bond of friendship between the two air forces and reiterated the PAF’s commitment to expanding cooperation in training, technology, and operational domains.

    “The meeting stands as a testament to the shared resolve of Pakistan and China to advance their time-tested strategic partnership through deepened cooperation and innovation-driven collaboration,” the statement concluded.

    Continue Reading

  • Stamina, skills, hunger: how do England solve a problem like Shubman Gill? | England v India 2025

    Stamina, skills, hunger: how do England solve a problem like Shubman Gill? | England v India 2025

    Two games into the series we have already witnessed something very special from Shubman Gill. In the second Test at Edgbaston he produced a real rarity: an individual performance that defines and dominates a game. Not just piling on the runs, but forcing his opponents to toil in the field until they felt exhausted and out of options.

    That fatigue affects batters’ mental clarity and their decision-making – what to play, when to leave – as well as their movement and their footwork. Reducing England to 25 for three at the end of the second day went a long way to deciding the match. As well as India bowled with the new ball, it was Gill’s remorselessness that created the conditions for it to happen.

    We have to pay testament to his stamina, his skill and his hunger – not just for runs, but to set an example as the new captain of a young team. Captaincy can affect a player’s form detrimentally, but it seems to have focused him and his three highest Test scores have been made in the past three weeks.

    We are coming to the end of a period that has been dominated by the so-called Fab Four – Virat Kohli, Joe Root, Steve Smith and Kane Williamson – and the search has been on for players who can take over. Gill has shown he can fill those boots and in a wonderfully orthodox style: he plays all formats and is brilliantly adaptable, but with a foundation of classic technique.

    He has not just been making his own reputation, he is making history. No touring player has scored as many runs in a Test as the 430 at Edgbaston – only Graham Gooch against India at Lord’s, in 1990, has bettered it – and his 585 puts him 23rd on the list of highest individual tallies in Test series in England, two games in. Even Don Bradman’s world record of 974 in the 1930 Ashes looks under threat.

    He was given the opportunity to dictate the game because England chose to bowl first. The opportunity to stretch and tire opponents and then benefit from scoreboard pressure and fatigue, as well as the opportunity to bowl on a possibly deteriorating pitch towards the end of the game, is why people win the toss and bat. England will be reflecting on that decision as they consider ways of reducing Gill’s impact on the remainder of the series.

    Shubman Gill made history at Edgbaston. Photograph: Alex Davidson/Getty Images

    I remember Smith’s performances on the Ashes tour I went on as batting coach in 2017-18, when he scored two unbeaten centuries and a double century, ending the series with an average of 137.40. At times it felt like we just could not get him out, it was soul-destroying. He always seemed to have an answer. After a while it really does get to you and we had two very experienced frontline bowlers in Jimmy Anderson and Stuart Broad.

    Gill is used to the cast of bowlers England used in the first two matches, he knows their plans, their trajectories, their variations, their pace. If fatigue was not already going to force Ben Stokes to change his bowling group, the need to find fresh ways to challenge the India captain would have done it anyway.

    If Chris Woakes can put himself through a third match in a row I would keep him in, because his batting could play a part. He bowled a good new-ball spell on the first day at Edgbaston when he was a bit unlucky and Lord’s is a happy hunting ground for him.

    skip past newsletter promotion

    Brydon Carse and Josh Tongue have been selected because they bowl with good pace, height and bounce and can present problems even on flat surfaces. They have done OK, but they have come up against top-class batting that has been ruthless – Stokes doesn’t like that word but India probably do. Now England need a point of difference: it’s going to be 30C in London, probably not great conditions for swing, and Jofra Archer has to be the man.

    But picking Archer, after one first-class game in four years, is a risk and with Stokes also needing to bowl in short bursts England then need a couple of people who can really put in a shift. What surprises me about their squad, aside from the three seamers who played the first two games, is the extraordinary lack of first-class overs in it: Gus Atkinson has come back in for the third Test having not played since the game against Zimbabwe in May and joins Jamie Overton, who would add extra depth to England’s batting but has played one T20 game since May and one first-class match this season.

    To pick either of them alongside Archer feels like a risk, particularly when it is going to be hot and dry and England have to be braced for long periods in the field.

    For that reason Sam Cook has to come in, though he is someone who offers control, plenty of stamina and lots of overs, but not always a cutting edge. Cook may struggle at Old Trafford and the Oval given the nature of the pitches and this could be the one where he uses the slope cleverly and bowls lots of overs. Woakes and Cook can then provide control with Archer the ace up England’s sleeve, someone fresh and fast, and something new for Gill to try to deal with.

    Continue Reading

  • Who made their mark in the wet at Silverstone? – Formula 1

    Who made their mark in the wet at Silverstone? – Formula 1

    1. Who made their mark in the wet at Silverstone?  Formula 1
    2. LIVE COVERAGE: Follow the action from the British GP  Formula 1
    3. Norris wins wet and chaotic home British GP  Dawn
    4. McLaren slammed over snub during podium celebrations after Nico Hülkenberg’s first F1 top-three finish  The Express Tribune
    5. Edd Straw’s 2025 British Grand Prix F1 driver rankings  The Race

    Continue Reading